P3 Health Partners (PIII) EBITDA (2021 - 2026)

P3 Health Partners (PIII) has 5 years of EBITDA data on file, last reported at -$153.9 million in Q4 2025.

• Quarterly EBITDA fell 11.09% year-over-year to -$153.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$270.3 million (up 15.7% YoY) and the FY2025 annual result came in at -$270.3 million, up 15.7% from the prior year.
• EBITDA declined to -$153.9 million in Q4 2025, from -$44.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$13.0 million in Q1 2021 to a low of -$912.2 million in Q2 2022.
• A 5-year average of -$120.7 million and a median of -$44.0 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA plunged 3412.32% — and 2023, when it soared 97.69%.
• Tracing PIII's EBITDA over 5 years: stood at -$26.9 million in 2021, then slumped by 1896.87% to -$536.5 million in 2022, then jumped by 88.02% to -$64.3 million in 2023, then slumped by 115.54% to -$138.5 million in 2024, then declined by 11.09% to -$153.9 million in 2025.
• The last three EBITDA figures came in at -$153.9 million (Q4 2025), -$44.2 million (Q3 2025), and -$34.1 million (Q2 2025), per Business Quant data.